4 results
To evaluate the safety and tolerability of DC-TAB following a single dose and following repeated dosing in healthy volunteers. To assess the pharmacokinetics of DC-TAB following a single dose and following repeated dosing in healthy volunteers. To…
Objectives:Primary:• To assess progression free survival (PFS) when treated with lanreotide Autogel® 120 mg administered every 14 days based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, and according to central review.Secondary:•…
The primary purpose of this study is to assess the dose response of several doses of tildacerfont in controlling hormone levels and reducing testicular tumors over 12 weeks by comparing the tildacerfont hormonal control response to a placebo, a *…
The purpose of this study is to see if tildacerfont can reduce the amount of GC (e.g., hydrocortisone) you need to take and reduce the level of certain hormones in your body.